Free no membership or login adult dateline new zealand
Some amounts in this press release may not add due to rounding.
Excluding the impact of legacy Hospira operations of $1.2 billion, foreign exchange and, to a lesser extent, the vaccines acquired from Baxter International Inc.Fourth-quarter 2015 includes three months of legacy Hospira global operations.The Company manages its commercial operations through two distinct businesses: an Innovative Products business and an Established Products business.(Baxter) of $35 million, Pfizer-standalone revenues increased by $646 million operationally, or 5%.Operational revenue growth in developed markets was driven primarily by the inclusion of $1.1 billion of revenues from legacy Hospira operations and continued strong performance of several key products, notably Prevnar 13 in adults and Ibrance in the U.DISCLOSURE NOTICE: The information contained in this earnings release and the attachments is as of February 2, 2016.
We assume no obligation to update forward-looking statements contained in this earnings release and the attachments as a result of new information or future events or developments.
This earnings release and the attachments contain forward-looking statements about our anticipated future operating and financial performance, business plans and prospects, in-line products and product candidates, strategic reviews, capital allocation, business-development plans, the benefits expected from our recent acquisition of Hospira, the pending combination with Allergan and plans relating to share repurchases and dividends, among other things, that involve substantial risks and uncertainties.
You can identify these statements by the fact that they use future dates or use words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “target,” “forecast,” “goal,” “objective,” “aim” and other words and terms of similar meaning.
Regarding our financial performance, we exceeded our 2015 financial guidance for reported revenuedespite an operating environment that remains challenging.
Importantly, Pfizer-standalone revenues increased 3% operationally, marking Pfizer's first year of operational revenue growth since entering a period of significant product losses of exclusivity.
Our 2016 financial guidance excludes any impact from the pending combination with Allergan.